Hormone Receptor-Positive Advanced Breast Cancer:

HR+ Advanced Breast Cancer: Introduction

Case Study Discussion

Case Study Discussion (cont)

ASCO Key Guideline Recommendations for HR+ MBC

ASCO Key Guideline Recommendations for HR+ MBC (cont)

SWOG 0226 Study: Anastrozole Alone vs Anastrozole + Fulvestrant in HR+ Breast Cancer

SWOG 0226: Results

FACT: Anastrozole Alone vs Anastrozole + Fulvestrant

FACT: Results

Emerging Therapies for HR+ Breast Cancer

BOLERO-2: Everolimus + Exemestane vs Placebo + Exemestane

BOLERO-2: Results

BOLERO-2: Most Common Grade 3/4 Adverse Events

Everolimus-Associated Stomatitis: Miracle Mouthwash vs Prednisolone Mouth Rinse

Miracle Mouthwash vs Prednisolone Mouth Rinse: Preliminary Results

CDKs and Their Cyclin Regulatory Subunits

PALOMA-1: Palbociclib + Letrozole vs Letrozole Alone

PALOMA-1: Results

PALOMA-2: Palbociclib + Letrozole vs Letrozole Alone

PALOMA-2: AE Summary

PALOMA-2: Results

MONALEESA-2: Ribociclib + Letrozole vs Letrozole in HR+ Advanced Breast Cancer

FALCON: Anastrozole vs Fulvestrant in HR+ Advanced or Metastatic Breast Cancer

FALCON: Results

MONALEESA-2 Ribociclib + Letrozole vs Letrozole in HR+ Advanced Breast Cancer

MONALEESA-2: Safety Profile

MONALEESA-2: Results

Treatment Recommendations for HR+ MBC

Conclusions

Abbreviations

Abbreviations